

RECEIVED

DEC 27 2000

TECH CENTER 1600/2900

39. The method of Claim 38, wherein the anti-human CD23 monoclonal antibody comprises a primate antigen binding portion.

40. The method of Claim 38, wherein the anti-human CD23 monoclonal antibody is human gamma-1 monoclonal antibody.

41. The method of Claim 38, wherein the anti-human CD23 monoclonal antibody comprises a rodent antigen-binding portion.

42. The method of Claim 38, wherein the anti-human CD23 monoclonal antibody is a humanized antibody.

43. The method of Claim 38, wherein the anti-human CD23 monoclonal antibody inhibits IgE expression *in vitro*.

44. The method of Claim 43, wherein the anti-human CD23 monoclonal antibody inhibits IL-4 induced IgE expression by B cells *in vitro*.

45. The method of Claim 38, wherein the anti-human CD23 monoclonal antibody inhibits IL-4 induced IgE expression *in vivo*.